As T cell engagers push into solid tumours and earlier-line settings, co-stimulation has emerged as one of the most promising levers for boosting efficacy and durability. This high-impact strategy workshop brings together pioneering T-cell engager experts to tackle which co-stimulatory receptor to target, how to time activation signals, and whether to build into a single trispecific or deliver sequentially. You’ll gain practical, actionable insights on overcoming tumour microenvironment barriers, managing exhaustion, and minimising safety risks. If you’re serious about engineering next-generation TCEs that deliver longlasting responses, this is the must-attend session to get ahead of the curve.

This workshop will cover:

• Clarifying the biological rationale – How co-stimulatory domains (CD28, CD137, CD2 etc.) enhance T cell fitness, prevent early exhaustion, and improve anti-tumour activity and aligning primary CD3 activation with co-stimulation signals to maximise efficacy and avoid mismatched signalling
• Choosing the right co-stimulatory target – Comparative advantages, limitations, and clinical unknowns for different T-cell engager targets
• Design and delivery strategies – How linking co-stimulatory elements directly to the engager can optimise timing, localisation, and therapeutic effect
• Managing exhaustion and safety risks – Avoiding on-target/off-tumour risks by activation of non tumour T cell subsets, reducing CRS, and limiting Fc-mediated toxicity
• Combinations vs trispecifics – Comparing strategies, advantages, and limitations – looking at clinical data